
COVID泚å°ãèšç»ç殺人ã§ãã "決å®ç蚌æ "ãåŒè·å£«ãçºèŠ
å èšäºã¯ãã¡ããã/Click here to read the original article.
ç±³åœäººåŒè·å£«ããŒãã¹ã»ã¬ã³ãã¯ãç±³åœé£åå»è¬åå±ïŒFDAïŒã®ãæ¥çåãã¬ã€ãã³ã¹ãææžãèŠçŽããèšç»æ®ºäººã® "決å®ç蚌æ "ãçºèŠããã
ããã以å€ã«ç§ãå°ãåºããçµè«ã¯ãããŸãã......ããã¯ã圌ãã "ã¯ã¯ãã³ "ãšèŠããããéºäŒåæ²»ç補åãããããæåºãããããåŒãèµ·ãããæ®ºå·èœåãããããšãç¥ã£ãŠããããšã蚌æããæ±ºå®çãªèšŒæ ãªã®ã§ãããšåœŒã¯èªã£ãã
ããŒãã¹ã»"ãã "ã»ã¬ã³ãã¯ãã³ããæä»£ã®åæã«ãç±³åœ6å·ã§ããã¯ããŠã³ããã¹ã¯çŸ©ååãã¯ã¯ãã³ã®å®å šæ§ã«ç°è°ãå±ããé£éŠèšŽèšãäž»å°ããããšã§æåã«ãªã£ããåœŒã¯æ³åŸäºåæãRenz LawããéããŠæŽ»åãããTom Renz's Newsletterããšé¡ããèªèº«ã®SubstackããŒãžã§å®æçã«èšäºãçºè¡šããŠããã
æšæ¥ã®èšäºã§ãã¬ã³ãã¯ãŸãã³ããã¯ã¯ãã³ã¯ã¯ã¯ãã³ã§ã¯ãªããšèª¬æããããã³ããã19ã®æ³šå°ã¯éºäŒåæ²»çã§ããããšãçè§£ããŠãããããšãéèŠã§ãããšåœŒã¯æžããã
ãããŠãç±³åœåœå±ã¯ã³ããæ³šå°ãåãã人ããã¯ã¯ãã³æ¥çš®ã«åæããŠããªã人ãå«ããŠãä»ã®äººã«ææããå¯èœæ§ãããããšãç¥ã£ãŠãããšãã蚌æ ãèªè ã«ç€ºããã
ãããŠã¬ã³ãã¯ããããã "ãã³ã°ã³ãã "ãæã€äººã ã«é¢ãã2023幎ã®ç ç©¶ã«ãã£ãŠç¢ºèªãããããã«ã圌ãã2006幎ã«ãããã®æ³šå°ãçãåŒãèµ·ããããšãç¥ã£ãŠããããšã瀺ããã
ã¬ã³ãã¯ãèªåãã¡ãäœãåºããåé¡ïŒã³ããæ³šå°ã«ãã£ãŠåŒãèµ·ããããçïŒã«å¯Ÿãã解決çããå¥ã®éºäŒåæ²»ç補åã§ããããšã瀺ãç§åŠè«æã匷調ããã
ãããã¯é°è¬ã§ãããã
ã¬ã³ãã®èšäºã¯ãµãã¹ã¿ãã¯ã§èªãããšãã§ããã
COVID泚å°ã¯éºäŒåæ²»çã§ãã
ããã«èšãã°ãã¢ãããšãã¡ã€ã¶ãŒèªèº«ã®SECæåºæžé¡ã«ã¯ãã³ããæ³šå°ãéºäŒåæ²»ç補åã§ããããšãèªããŠããããšã¬ã³ãã¯ææããã 以äžã¯ãã¢ããã®ååæããšã®èšŒåžååŒå§å¡äŒïŒSECïŒæåºæžé¡ã®æç²ã§ããïŒ
mRNAå»è¬åã®éçºã¯ããã®æ°ããã¯ã©ã¹ã®å»è¬åã®æ¬æ°ã§åäŸã®ãªãæ§è³ªã®ãããèšåºéçºããã³èŠå¶äžã®ãªã¹ã¯ãããªããããŸãã
æœåšçãªæ°ã¯ã©ã¹ã®å»è¬åãšããŠãmRNAå»è¬åã¯çŸåšãŸã§ã«FDAããã®ä»ã®èŠå¶æ©é¢ããæ¿èªãããŠããŸãã...çŸåšãmRNAã¯FDAã«ãã£ãŠéºäŒåæ²»ç補åãšã¿ãªãããŠããŸããäžç¥
2015幎3æãç±³åœä¿å¥ç€ŸäŒçŠç¥çïŒä»¥äžãHHSãïŒãFDAãçç©è£œå€è©äŸ¡ç ç©¶ã»ã³ã¿ãŒïŒä»¥äžãCBERãïŒã¯ã"Guide for Industry "ãçºè¡šããã ãã®ã¬ã€ãã§ã¯ãéºäŒåæ²»çã以äžã®ããã«å®çŸ©ããŠããïŒ
éºäŒåæ²»çã¯ã2006幎11æä»ãã®FDAã¬ã€ãã³ã¹ææž "Gene Therapy Clinical Trials - Observing Subjects for Delayed Adverse Events "ã«ãããŠã"ç§»æ€ãããéºäŒç©è³ªã®è»¢åããã³ïŒãŸãã¯ç¿»èš³ãããã³ïŒãŸãã¯å®¿äž»ã²ãã ãžã®çµã¿èŸŒã¿ã«ãã£ãŠå¹æãçºæ®ããæ žé žããŠã€ã«ã¹ããŸãã¯éºäŒåæäœããã埮çç©ãšããŠæäžããã補å "ãšå®çŸ©ãããŠããããã®è£œåã¯ãin vivoã§çްèãæ¹å€ããããã«äœ¿çšããããšãã§ããããã¬ã·ããšã³ããžã®æäžåã«ex vivoã§çްèã«å°å ¥ããããšãã§ããã
æ¬ã¬ã€ãã³ã¹ã«ãããŠããã¯ã¿ãŒã¯ã¯ãã³ã¯ãŠã€ã«ã¹ã埮çç©ïŒå žåçã«ã¯çްèïŒããããã¯DNAãã©ã¹ãããçšããŠæåãã³ãŒãããDNA/RNAãäœå ã®çްèã«å°å ¥ããã¯ã¯ãã³ã§ãããããã¯ã¿ãŒããšã¯ããã£ãªã¢ãšããŠäœ¿çšããããŠã€ã«ã¹ã埮çç©ããŸãã¯DNAãã©ã¹ãããæãã
ã§ã¯ããã®ããšã¯ããããããèšããšã©ãããããšãªã®ãïŒãCOVIDã¯ã¯ãã³ã¯éºäŒåç£ç©ã§ãããšããããšã§ãããšã¬ã³ãã¯æžããŠããã
æ°å¹Žåããã·ã§ãã£ã³ã°ã®å¯èœæ§ãç¥ã£ãŠãã
ãããŠã¬ã³ãã¯ããã®å¯èœæ§ãèŠåãã人ã ã "é°è¬è«è "ãšäžå·ããªããã"ã¯ã¯ãã³æµåº "ãèµ·ããããããšãèªè ãã©ã®ããã«ç¥ã£ãŠããããèªã£ãã
ã¯ã¯ãã³è±èœãšã¯ãã¯ã¯ãã³æ¥çš®ãåãã人ãã¯ã¯ãã³ã®æåãæŸåºããããšã§ããã匱æ¯åããç åäœãå«ã匱æ¯åã¯ã¯ãã³ã«ãããŠã€ã«ã¹ææåŸã«èµ·ãããããŠã€ã«ã¹æåºã®äžåœ¢æ ã§ããã èšãæããã°ãã¯ã¯ãã³ãæ¥çš®ãã人ãä»ã®äººã«ç æ°ãç§»ããšããããšã§ããã ãã®çŸè±¡ãèµ·ããããšã¯ç¥ãããŠãããã"å ¬åŒèŠè§£ "ã¯ã³ãã "ã¯ã¯ãã³ "ã§èµ·ãã£ãŠããããšãåŠå®ããŠããã
ãç§ãã¡ãè±èœã«ã€ããŠèŠåããã¯ã¯ãã³æªæ¥çš®ã®ã¡ã¹ããžã£ãã«ãããããåŸããªãç°åžžåºè¡ããã®ãã«çåãåãããšããç§ãã¡ã¯ãé°è¬è«è ããšåŒã°ããã¬ã¹æããããæ€é²ãããŸããããšã¬ã³ãã¯æžããŠããã
ã³ããæ³šå°ã®ã¬ã·ããšã³ããéºäŒåæ²»çã«åæããŠããªã人ã ãæåºãã害ãäžããå¯èœæ§ãããããšãç¥ã£ãŠããããšã蚌æããããã«ã圌ã¯åãã2015幎ã«HHSãFDAãCBERã«ãã£ãŠçºè¡šãããå¥ã®ãç£æ¥çãžã®ã¬ã€ãã³ã¹ãããã®æç²ãå ±æããïŒ
çç©è£œå€è©äŸ¡ç ç©¶ã»ã³ã¿ãŒïŒCBERïŒïŒçްèã»çµç¹ã»éºäŒåæ²»ç宀ïŒOCTGTïŒã¯ãåèšåºããã³èšåºéçºã«ãããæåºè©Šéšã®å®æœæ¹æ³ã«é¢ããæšå¥šäºé ãããŠã€ã«ã¹ãŸãã¯çްèããŒã¹ã®éºäŒåæ²»ç補åïŒVBGT補åïŒããã³ãªã³ã³ã«ããŠã€ã«ã¹ãŸãã¯çްèïŒãªã³ã³ã«ã補åïŒã®ã¹ãã³ãµãŒã§ããçæ§ã«æäŸããããã«ãæ¬ã¬ã€ãã³ã¹ãçºè¡ããŸãã
æ¬ã¬ã€ãã³ã¹ã«ãããŠããè±èœããšã¯ãææ³ç©ïŒç³äŸ¿ïŒãåæ³ç©ïŒå°¿ãåŸæ¶²ã錻åœé æ¶²ãªã©ïŒãç®èïŒè¿ç±ããã ããåµå·ïŒã ä»ããŠãVBGT補å€ãŸãã¯è «ç溶解æ§ïŒ»ãã補å€ãæ£è ããæŸåºãããããšãæå³ããã
VBGTãŸãã¯è «ç溶解ç£ç©ãæåºããããšãæ²»çãåããŠãã人ããæªæ²»çã®äººïŒäŸãã°ã身è¿ãªäººãå»çåŸäºè ïŒã«äŒæããå¯èœæ§ãããã
æåºããã VBGT ãŸãã¯è «ç溶解çæç©ãæææ§ãæããå¯èœæ§ã¯ãæªæ²»çã®å人ãžã®äŒæãªã¹ã¯ã«é¢é£ããå®å šæ§ã®æžå¿µãæèµ·ãããäžç¥
ã圌ãã¯ãCOVID-19éºäŒåæ²»ç補å€ã泚å°ããã人ãããåæããŠããªã人ãžãããç§»è¡ïŒæåºïŒããå¯èœæ§ã«ã€ããŠç¥ã£ãŠããã圌ãã¯ãæ²»çããã人ã®äœæ¶²ãææ³ç©ãéããŠãåæããŠããªã人ã圱é¿ãåãã害ãåããå¯èœæ§ã®ããè€æ°ã®ãã¯ã¿ãŒãç¹å®ãããããã¯å ¬ç¶ãšèªããããããšã§ããããã¥ã«ã³ãã«ã¯ç¶±é ã®ç¬¬äžååã§ããèªçºçåæã«å¯Ÿããæãããªéåã§ãããšã¬ã³ãã¯èšã£ãã
ãããšé çºæ§å¯äœçš
ã¬ã³ãã¯ããããã®éºäŒåæ²»ç補åããæ³šå°åŸäœå¹Žçµã£ãŠãçãåŒãèµ·ããå¯èœæ§ãããããšãç¥ã£ãŠããããšæžããŠããã
FDAãHHSãCBERã2006幎ã«çºè¡šããææžã«ããã°ãéºäŒåæ²»ç補åã«ã¯ãæ£åžžãªçŽ°èæ©èœã«æªåœ±é¿ãåãŒããªã¹ã¯ãããããã®åœ±é¿ã¯æ°ã«æããæ°å¹Žé ããå¯èœæ§ãããïŒ
éºäŒåå°å ¥æè¡ã«æé²ãããç 究察象è ã¯ãé çºæ§ã®æå®³äºè±¡ã®ãªã¹ã¯ã«ãããããå¯èœæ§ãããã...æç¶çãªçç©åŠç掻æ§ã¯ãæ£åžžãªçŽ°èæ©èœã«æå®³ãªåœ±é¿ãåãŒãå¯èœæ§ãããã察象è ã¯æå®³äºè±¡ã®çºçŸãªã¹ã¯ã«ãããããã
éºäŒåå°å ¥æè¡ãžã®æé²åŸãé çºæ§æå®³äºè±¡ã®ãªã¹ã¯ãå¢å€§ãããå¯èœæ§ã®ããèŠå ã«ã¯ããŠã€ã«ã¹ãã¯ã¿ãŒã®æç¶æ§ã宿䞻ã²ãã ãžã®éºäŒç©è³ªã®çµ±åãå°å ¥éºäŒåã®é·æçºçŸã宿䞻éºäŒåã®çºçŸã®å€åãªã©ããã ... ãŠã€ã«ã¹ãã¯ã¿ãŒããã®éºäŒç©è³ªã宿䞻现èã®ã²ãã DNAã«çµ±åããããšãæªæ§åœ¢è³ªè»¢æã®ãªã¹ã¯ãé«ãŸãã
å°å ¥éºäŒåã®é·æçºçŸã¯ãŸãã調ç¯äžèœãªçްè墿®ãæªæ§åœ¢è³ªè»¢æãèªå·±æåã«å¯Ÿããèªå·±å ç«æ§åå¿ãäºæž¬äžå¯èœãªæå®³äºè±¡ã«èµ·å ããé·æçãªã¹ã¯ãšé¢é£ããå¯èœæ§ãããã宿䞻éºäŒåã®å€åããçºçŸããŸããäºæž¬ã§ããªãæãŸãããªãçç©åŠçäºè±¡ãããããå¯èœæ§ããããäžç¥
ãæªæ§è»¢æããšã¯ã现èãçã®æ§è³ªãç²åŸããããã»ã¹ã®ããšã§ããã èšãæããã°ã现èãç现èã«å€ããããšã§ããã
äºå®ç¢ºèªæ åœè ã¯ã泚å°ãDNAã«åœ±é¿ãäžãããå€åããããããããšã¯ãªããšãé¡ãéããªããŸã§èšãã ããããšã¬ã³ãã¯æžããŠããããæããã«ãããã¯åã§ãããã
äžèšã«å ããã¬ã³ã㯠"ãã³ã°ã³ãã "ã«èŠãã人ã ã®çްèDNAãåæãã2023幎ã®ç ç©¶ãææãããèè ãã¯ãåå è ã®è¡æ¶²çްèãããã¡ã€ã¶ãŒç€Ÿã®ã³ãããBNT162b2 "ã¯ã¯ãã³ "ã«ç¹ç°çãªéºäŒåãçºèŠãããããã®çºèŠã¯ãmRNAã³ããã»ã¯ã¯ãã³ãã³ããã»ã¯ã¯ãã³ãæ¥çš®ãã人ã ã®DNAã«æ°žä¹ ã«çµã¿èŸŒãŸããããšã蚌æãããã®ã§ãã 圌ã¯ç¶ããïŒ
ãç°¡åã«èšãã°ãèŠå¶åœå±ã¯ããããã®è£œåã宿䞻ã²ãã ã«çµã¿èŸŒãŸããã¬ã³ïŒæªæ§åœ¢è³ªè»¢æïŒãèªå·±å ç«çŸæ£ãæå®³äºè±¡ãåŒãèµ·ããå¯èœæ§ãããããšãæ°å¹ŽåŸã«ç¥ã£ãŠããã®ã§ãããŸãããããã®è£œåãã²ãã ã«çµ±åãããªãå Žåã§ããïŒäžè¿°ããïŒè±èœã«ããç¶ç¶çãªæŽé²ãçºçã®ãªã¹ã¯ãé«ããå¯èœæ§ãããããšãèæ ®ããŠã»ãããã
COVID泚å°ã¯æ®ºãããã«èšèšãããŠãã
ãããã®æ³šå°ã¯æ®ºäººæ©æ¢°ãšããŠèšèšããã人ã ãæåºã殺ãããšãç¥ããªããæµéããããšã¬ã³ãã¯æžããŠããã圌ãã¯éºäŒåæ²»ç補åãäœããããã "ã¯ã¯ãã³ "ãšããŠå£²ãåºããã§ããã ãå€ãã®äººã®æã«æž¡ãããã«ç»çãã匷èŠããè²·åããåãã€ããã
ãããŠä»ãçãèå»¶ããŠããããé©ãã¹ãããšã«åœŒã㯠"解決ç "ãçšæããŠããã ãããŠã"ãã®è§£æ±ºçãšã¯ããŸãå¥ã®éºäŒåæ²»ç補åã§ããã
ãã®èšŒæ ãšããŠã圌ã¯2015幎ã«ããã€ãã£ãŒã»ãã£ã³ãµãŒã»ãžãŒã³ã»ã»ã©ããŒãèªã«æ²èŒãããè«æãåãäžããïŒ
æ¥éã«å€åããŠããéºäŒåæ²»çã®åéã§ã¯ãããæ£è ã«å¯Ÿãã驿°çãªæ²»çæ³ãæ°å€ãæåŸ ãããŠããããã现èãå ç«çްèã®éºäŒåæ¹å€ããªã³ã³ã©ã€ããŠã€ã«ã¹ããã¯ããªã¢ã®äœ¿çšã«ããã鲿©ã¯ãããæ²»çã®ããã®æ°å€ãã®èšåºè©Šéšã«ã€ãªããããã®ãã¡ã®ããã€ãã¯è£œåéçºã®åŸæã«é²ãã§ããã
ãã®èšäºã§ã¯ãOCTGTïŒOffice of Cellular, Tissue and Gene TherapiesïŒçްèã»çµç¹ã»éºäŒåæ²»çå±ïŒãèŠå¶ããŠãããããŸããŸãªçš®é¡ã®CGTïŒããéºäŒåæ²»çïŒãã補åã«ã€ããŠè¿°ã¹ãã
CGT補åã«ã¯ããŠã€ã«ã¹ã现èã®æåºãããªãã¡ä»ã®åäœã«ææããå¯èœæ§ã®ãããŠã€ã«ã¹ç²åã现èã®ææ³ã»åæ³ã®å¯èœæ§ãããã補åã«ç±æ¥ãããŠã€ã«ã¹ã现èã¯ãèŠªæ ªã®ãŠã€ã«ã¹ã现èã»ã©æææ§ãæ¯æ§ã¯åŒ·ããªããããããªãããäŒæã®å¯èœæ§ã¯å®å šæ§ã®æžå¿µãåŒãèµ·ãããéºäŒåæ²»çã®èšåºè©Šéšã§æ£è ããåéãããããŒã¿ã®åæããããŠã€ã«ã¹ãã¯ã¿ãŒã®æåºã¯å®éã«èµ·ãããäž»ã«ãã¯ã¿ãŒã®çš®é¡ãšæäžçµè·¯ã«ãã£ãŠæ±ºãŸãããšã瀺ããããæ¬ç ç©¶ã§æç€ºããã宿§çã¢ãã«ã¯ãç°ãªãææ³çµè·¯ã§çºçããæåºãªã¹ã¯ã決å®ããã®ã«åœ¹ç«ã€ã
ããã¯ã€ã³ãã©ãŒã ãã»ã³ã³ã»ã³ãã®æ¬ åŠãè¶ ããŠããããããã¯é°è¬ã§ããã
ããŒãã¹ã»ã¬ã³ãã®åæã¯ãã¡ãã